.
.
. taking ustekinumab�a biologic that targets a different aspect of the immune system," gelfand said.
.
738, may 18, 2018 (eat),
.erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.